brigimadlin   Click here for help

GtoPdb Ligand ID: 12627

Synonyms: BI 907828 | BI-907828 | BI907828 | example Ia-34 [WO2017060431A1]
PDB Ligand
Compound class: Synthetic organic
Comment: BI 907828 is a small molecule that disrupts the protein-protein interaction between the tumour suppressor p53 and MDM2 (a p53 repressor protein) [1]. Antagonising this interaction is proposed to block proteosomal degradation of p53 protein, which is expected to re-activate p53-mediated induction of tumour cell apoptosis. The chemical structure was disclosed during the 'First Disclosures of New Drug Candidates' session at the April 2023 (Orlando) meeting of the AACR, and it maps to PubChem CID 129264140, and to the proposed INN brigimadlin.

brigimadlin is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 85.24
Molecular weight 591.46
XLogP 2.13
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC1=C(C=CC2=C3C[C@@]4([H])[C@]([H])([C@]([H])(C5=CC=CC(=C5F)Cl)[C@@]6(C7=CC=C(C=C7NC6=O)Cl)N4CC8CC8)N3N=C12)C(=O)O
Isomeric SMILES [H][C@]12CC3=C4C=CC(C(O)=O)=C(C)C4=NN3[C@@]1([H])[C@]([H])(C5=CC=CC(Cl)=C5F)[C@@]6(N2CC7CC7)C(=O)NC8=CC(Cl)=CC=C68
InChI InChI=1S/C31H25Cl2FN4O3/c1-14-17(29(39)40)8-9-18-23-12-24-28(38(23)36-27(14)18)25(19-3-2-4-21(33)26(19)34)31(37(24)13-15-5-6-15)20-10-7-16(32)11-22(20)35-30(31)41/h2-4,7-11,15,24-25,28H,5-6,12-13H2,1H3,(H,35,41)(H,39,40)/t24-,25-,28+,31+/m0/s1
InChI Key AMTXDBGKYPDTTA-SJVQGLCSSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
BI 907828 has been progressed to clinical evaluations, to determine efficacy as a treatment for advanced solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05218499 Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma Phase 2/Phase 3 Interventional Boehringer Ingelheim
NCT05376800 A Study to Determine How BI 907828 is Taken up in the Tumor and to Determine the Highest Dose of BI 907828 That Could be Tolerated in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma Phase 1 Interventional Boehringer Ingelheim
NCT05512377 Brightline-2: A Study to Test Whether BI 907828 Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder Phase 2 Interventional Boehringer Ingelheim